Pediatric Hematology and Oncology最新文献_第2页

Levofloxacin prophylaxis in pediatric oncology and hematopoietic stem cell transplantation: a literature review. 小儿肿瘤学和造血干细胞移植中的左氧氟沙星预防疗法：文献综述。

IF 1.2 4区医学

Pediatric Hematology and Oncology Pub Date : 2024-09-01 Epub Date: 2024-07-08 DOI: 10.1080/08880018.2024.2353888

Jane Koo, Jeffrey Hord, Craig Gilliam, Mary Lynn Rae, Katherine Staubach, Katherine Nowacki, Anne Lyren, Maitreya Coffey, Christopher E Dandoy

{"title":"Levofloxacin prophylaxis in pediatric oncology and hematopoietic stem cell transplantation: a literature review.","authors":"Jane Koo, Jeffrey Hord, Craig Gilliam, Mary Lynn Rae, Katherine Staubach, Katherine Nowacki, Anne Lyren, Maitreya Coffey, Christopher E Dandoy","doi":"10.1080/08880018.2024.2353888","DOIUrl":"10.1080/08880018.2024.2353888","url":null,"abstract":"Bloodstream infections (BSI) are one of the leading causes of morbidity and mortality in children and young adults receiving chemotherapy for malignancy or undergoing hematopoietic stem cell transplantation (HSCT). Antibiotic prophylaxis is commonly used to decrease the risk of BSI; however, antibiotics carry an inherent risk of complications. The aim of this manuscript is to review levofloxacin prophylaxis in pediatric oncology patients and HSCT recipients. We reviewed published literature on levofloxacin prophylaxis to prevent BSI in pediatric oncology patients and HSCT recipients. Nine manuscripts were identified. The use of levofloxacin is indicated in neutropenic children and young adults receiving intensive chemotherapy for leukemia or undergoing HSCT. These results support the efficacy of levofloxacin in pediatric patients with leukemia receiving intensive chemotherapy and should be considered in pediatric patients undergoing HSCT prior to engraftment.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11335452/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141555314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oncological pediatric early warning score: a dedicated tool to predict patient's clinical deterioration and need for pediatric intensive care treatment. 肿瘤儿科预警评分：预测患者临床病情恶化和儿科重症监护治疗需求的专用工具。

IF 1.2 4区医学

Pediatric Hematology and Oncology Pub Date : 2024-09-01 Epub Date: 2024-07-08 DOI: 10.1080/08880018.2024.2355543

Teresa Maccarana, Marta Pillon, Veronica Bertozzi, Elisa Carraro, Elena Cavallaro, Claudia Maria Bonardi, Luca Marchetto, Giulia Reggiani, Annalisa Tondo, Camilla Rosa, Rosanna Irene Comoretto, Angela Amigoni, Alessandra Biffi

{"title":"Oncological pediatric early warning score: a dedicated tool to predict patient's clinical deterioration and need for pediatric intensive care treatment.","authors":"Teresa Maccarana, Marta Pillon, Veronica Bertozzi, Elisa Carraro, Elena Cavallaro, Claudia Maria Bonardi, Luca Marchetto, Giulia Reggiani, Annalisa Tondo, Camilla Rosa, Rosanna Irene Comoretto, Angela Amigoni, Alessandra Biffi","doi":"10.1080/08880018.2024.2355543","DOIUrl":"10.1080/08880018.2024.2355543","url":null,"abstract":"Pediatric oncohematological patients frequently require PICU admission during their clinical history. The O-PEWS is a specific score developed to predict the need for PICU admission of oncohematological children. This study aimed at i) describing the trend of the O-PEWS in a cohort of patients hospitalized in the Pediatric Oncohematology ward and transferred to the PICU of Padua University Hospital, measured at different time-points in the 24 hours before PICU admission and to evaluate its association with mortality and presence of organ failure; ii) investigating the association between the recorded O-PEWS, and PIM3, number of organ failure and the need for ventilation, dialysis and inotropes.This retrospective single-center study enrolled oncohematological children admitted to the PICU between 2017 and 2021. The O-PEWS, ranging between 0 and 15, was calculated on the available medical records and the TIPNet-Network database at 24 (T-24), 12 (T-12), 6 (T-6) and 0 (T0) hours before PICU admission.RESULTS: 101 PICU admissions, related to 80 children, were registered. During the 24 hours prior to PICU admission, the O-PEWS progressively increased in all the patients. At T-24 the median O-PEWS was 3 (IQR 1-5), increasing to a median value of 6 (IQR 4-8) at T0. The O-PEWS was positively associated with mortality, organ failure and the need for ventilation at all the analyzed time-points and with the need for dialysis at T-6.The O-PEWS appears as a useful tool for predicting early clinical deterioration in oncohematological patients and for anticipating the initiation of life-support treatments.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141555315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world implementation of North American and SIOP strategies for the treatment of Wilms tumor in Uruguay. 在乌拉圭实际实施北美和 SIOP 战略治疗 Wilms 肿瘤。

IF 1.2 4区医学

Pediatric Hematology and Oncology Pub Date : 2024-09-01 Epub Date: 2024-07-08 DOI: 10.1080/08880018.2024.2345662

Diana Vargas, Luisa Chantada, Bruno Cuturi, Anaulina Silveira, Ángeles Rodríguez, Luján Guerrero, Lucia Díaz, Mariela Castiglioni, Fabiana Morosini, Carolina Pages, Elizabeth Simón, Luis Castillo

{"title":"Real-world implementation of North American and SIOP strategies for the treatment of Wilms tumor in Uruguay.","authors":"Diana Vargas, Luisa Chantada, Bruno Cuturi, Anaulina Silveira, Ángeles Rodríguez, Luján Guerrero, Lucia Díaz, Mariela Castiglioni, Fabiana Morosini, Carolina Pages, Elizabeth Simón, Luis Castillo","doi":"10.1080/08880018.2024.2345662","DOIUrl":"10.1080/08880018.2024.2345662","url":null,"abstract":"Wilms tumor has been selected as an index tumor by the WHO Global Initiative for Childhood Cancer with the aim to improve cure rates worldwide. Nevertheless, there is a scarcity of published data on outcomes beyond those of the major cooperative groups. Therefore, we conducted a retrospective analysis including all patients with Wilms tumor treated at our referral center in Uruguay between 1995 and 2020. Treatment consisted of North American (NA) strategies in 23 cases (1995-2004), followed by the SIOP strategy in 35 cases thereafter. Staging included: I-II = 28, III = 7, IV = 14, and V = 9. There were no major surgical or medical complications; however, a delay in the administration of local radiotherapy was observed (median of 21 days after surgery). There were no cases of toxicity- or surgery-related deaths or treatment abandonment. Five-year probability of overall survival was 0.72 and 0.92 for the NA and SIOP groups, respectively. We conclude that outcomes were better for the SIOP strategy with no unexpected toxicities and high treatment compliance in both strategies. Timely implementation of radiotherapy was challenging.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141555316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adjuvant immune checkpoint inhibitor therapy may benefit pediatric patients with stage III melanoma and sentinel lymph node positivity: a case series. 辅助免疫检查点抑制剂疗法可使Ⅲ期黑色素瘤和前哨淋巴结阳性的儿科患者获益：一个病例系列。

IF 1.2 4区医学

Pediatric Hematology and Oncology Pub Date : 2024-09-01 Epub Date: 2024-05-07 DOI: 10.1080/08880018.2024.2350455

Acacia Bowden, Jeanette Zambito, Jinia El-Feghaly, Jeffrey R Andolina

{"title":"Adjuvant immune checkpoint inhibitor therapy may benefit pediatric patients with stage III melanoma and sentinel lymph node positivity: a case series.","authors":"Acacia Bowden, Jeanette Zambito, Jinia El-Feghaly, Jeffrey R Andolina","doi":"10.1080/08880018.2024.2350455","DOIUrl":"10.1080/08880018.2024.2350455","url":null,"abstract":"Melanoma is the most common skin cancer in children. While the current literature establishes treatment protocols for adult-type melanoma, very few pediatric-specific studies exist, and children are often excluded from melanoma clinical trials2. We report a case series of 23 pediatric patients aged 2-20 years old diagnosed with melanoma at the University of Rochester Medical Center between 1/1/2011 and 1/1/2022. 9/23 patients were Stage III; all patients underwent wide local excision and 9 received adjuvant therapies. 2/23 (8.7%) patients had recurrence of their malignancy after therapy while 21/23 (91.3%) remained without disease progression; 1 patient died from unknown cause, but the rest are alive and currently without disease. All patients whose initial therapy included nivolumab in addition to wide local excision did not have recurrence or progression of their disease. This case series highlights trends in the presentation, treatment, and outcomes of pediatric melanoma; however, additional multi-center studies are needed to establish the clinical utility of such features in pediatric melanoma.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characteristics and complications of acute promyelocytic leukemia in children: an analysis of a national database. 儿童急性早幼粒细胞白血病的特征和并发症：全国数据库分析。

IF 1.2 4区医学

Pediatric Hematology and Oncology Pub Date : 2024-09-01 Epub Date: 2024-07-08 DOI: 10.1080/08880018.2024.2352727

Ariella Barhen, Paul A Martinez, Prithvi Sendi, Balagangadhar R Totapally

{"title":"Characteristics and complications of acute promyelocytic leukemia in children: an analysis of a national database.","authors":"Ariella Barhen, Paul A Martinez, Prithvi Sendi, Balagangadhar R Totapally","doi":"10.1080/08880018.2024.2352727","DOIUrl":"10.1080/08880018.2024.2352727","url":null,"abstract":"Acute promyelocytic leukemia (APL) is an uncommon subtype of acute myelogenous leukemia (AML) that was previously one of the most fatal forms of acute leukemia. With advances in diagnosis and treatment, APL has become one of the most curable myeloid leukemias. The major reason for treatment failure in APL is early death after initiation of treatment. We performed a retrospective cross-sectional analysis of the Healthcare Cost and Utilization Project 2016 and 2019 Kids' Inpatient Database, with the diagnosis of APL or AML not in remission as defined by ICD-10-CM codes. We compared complications and outcomes associated with APL and AML (exclusive of APL) in hospitalized children in the U.S. and described yearly national incidence. The national incidence of APL was 2.2 cases per million children per year. Children with APL were more likely to have cardiopulmonary complications (OR 1.79; CI 1.20-2.67; p = 0.004), coagulation abnormalities or DIC (OR 7.75; CI 5.81-10.34; p < 0.001), pulmonary hemorrhage (OR 2.18; CI 1.49-3.17; p < 0.001), and intracranial hemorrhage (OR 10.82; CI 5.90-19.85; p < 0.001) and less likely to have infectious complications (OR 0.48; CI 0.34-0.67; p < 0.001) compared to children with AML. In-hospital mortality rates were similar in children with APL and AML (4.2% vs 2.6%; OR 1.62; CI 0.86-3.06; p = 0.13), while the median length of stay for children who died from APL was shorter compared to AML (2 (IQR: 1-7) versus 25 (IQR: 5-66) days; p < 0.05). Hemorrhagic complications occur more often, and infectious complications occur less often in hospitalized children with APL compared to AML.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141555313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The relationship between liver stiffness by two-dimensional shear wave elastography and iron overload status in transfusion-dependent patients. 通过二维剪切波弹性成像检测输血依赖型患者肝脏硬度与铁超负荷状态之间的关系。

IF 1.2 4区医学

Pediatric Hematology and Oncology Pub Date : 2024-09-01 Epub Date: 2024-07-09 DOI: 10.1080/08880018.2024.2353900

Pimporn Puttawibul, Supika Kritsaneepaiboon, Thirachit Chotsampancharoen, Polathep Vichitkunakorn

{"title":"The relationship between liver stiffness by two-dimensional shear wave elastography and iron overload status in transfusion-dependent patients.","authors":"Pimporn Puttawibul, Supika Kritsaneepaiboon, Thirachit Chotsampancharoen, Polathep Vichitkunakorn","doi":"10.1080/08880018.2024.2353900","DOIUrl":"10.1080/08880018.2024.2353900","url":null,"abstract":"Increased liver stiffness (LS) can be result of increased liver iron concentration (LIC) which may not yet be reflected in the liver fibrotic status. The objective of our study was to examine relationship between hemochromatosis, LS, and serum ferritin level in transfusion-dependent patients. We recruited all 70 transfusion-dependent patients, whose median age was 15, referred for evaluating LIC status by magnetic resonance imaging (MRI) followed by two-dimensional ultrasonography shear wave elastography (2D-SWE). Thalassemia beta affected the majority of the patients. The optimal cut point for prediction of severe hemochromatosis using median SWE (kPa) and SWV (m/s) was ≥ 7.0 kPa and ≥ 1.54 m/s, respectively, with sensitivity of 0.76 (95% confidence interval [CI] 0.55, 0.91) and, specificity of 0.69 (95%CI 0.53, 0.82). When combing the optimal cut point of SWE (kPa) at ≥ 7.0 and serum ferritin ≥ 4123 ng/mL, the sensitivity increased to 0.84 (95%CI 0.64, 0.95) with specificity of 0.67 (95%CI 0.50, 0.80), positive predictive value (PPV) of 0.60 (95%CI 0.42, 0.76), and negative predictive value (NPV) of 0.88 (95%CI 0.71, 0.96). Simultaneous tests of 2D-SWE and serum ferritin for prediction of severe hemochromatosis showed the highest sensitivity of 84% (95%CI 0.64-0.95), as compared to 2D-SWE alone at 76% (95%CI 0.55, 0.91) or serum ferritin alone at 44% (95%CI 0.24-0.65). We recommend measuring both 2D-SWE and serum ferritin in short interval follow up patients. Adding 2D-SWE to management guideline will help in deciding for aggressive adjustment of iron chelating medication and increased awareness of patients having severe hemochromatosis.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141559453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Myelofibrosis associated with immune cytopenia in an infant: a diagnostic and therapeutic challenge. 婴儿骨髓纤维化伴有免疫细胞减少症：诊断和治疗难题。

IF 1.2 4区医学

Pediatric Hematology and Oncology Pub Date : 2024-08-01 Epub Date: 2024-05-07 DOI: 10.1080/08880018.2024.2350424

Yessenia L Molina, Luis Blasco-Santana, Alejandro Sanz, Cristina Julia Blázquez Gómez, Josune Zubicaray, June Iriondo, Jesús González de Pablo, Julián Sevilla, Elena Sebastián

引用次数: 0

The Italian Consensus Conference on the role of rehabilitation for children and adolescents with leukemia, central nervous system tumors, and bone cancer, part 2: general principles for the rehabilitation treatment of motor function impairments. 意大利关于白血病、中枢神经系统肿瘤和骨癌儿童和青少年康复作用的共识会议，第二部分：运动功能障碍康复治疗的一般原则。

IF 1.2 4区医学

Pediatric Hematology and Oncology Pub Date : 2024-08-01 Epub Date: 2024-07-10 DOI: 10.1080/08880018.2024.2353360

Francesca Rossi, Stefano Botti, Mattia Morri, Sebastian Asaftei, Daniele Bertin, Simona Breggiè, Roberto Casalaz, Marta Cervo, Paola Ciullini, Monica Coppo, Annalisa Cornelli, Maria Esposito, Miriana Ferrarese, Marina Ghetti, Lucia Longo, Gabriella Naretto, Nicoletta Orsini, Daniele Panzeri, Chiara Pellegrini, Michela Peranzoni, Antonella Perna, Nadine Petit, Fabiola Picone, Gianna Pittorru, Debora Raffa, Veronica Recchiuti, Lucia Rizzato, Marina Sarzana, Raffaella Sensi, Franca Fagioli, Federica Ricci

{"title":"The Italian Consensus Conference on the role of rehabilitation for children and adolescents with leukemia, central nervous system tumors, and bone cancer, part 2: general principles for the rehabilitation treatment of motor function impairments.","authors":"Francesca Rossi, Stefano Botti, Mattia Morri, Sebastian Asaftei, Daniele Bertin, Simona Breggiè, Roberto Casalaz, Marta Cervo, Paola Ciullini, Monica Coppo, Annalisa Cornelli, Maria Esposito, Miriana Ferrarese, Marina Ghetti, Lucia Longo, Gabriella Naretto, Nicoletta Orsini, Daniele Panzeri, Chiara Pellegrini, Michela Peranzoni, Antonella Perna, Nadine Petit, Fabiola Picone, Gianna Pittorru, Debora Raffa, Veronica Recchiuti, Lucia Rizzato, Marina Sarzana, Raffaella Sensi, Franca Fagioli, Federica Ricci","doi":"10.1080/08880018.2024.2353360","DOIUrl":"10.1080/08880018.2024.2353360","url":null,"abstract":"In Italy, 1400 children and 800 adolescents are diagnosed with cancer every year. About 80% of them can be cured but are at high risk of experiencing severe side effects, many of which respond to rehabilitation treatment. Due to the paucity of literature on this topic, the Italian Association of Pediatric Hematology and Oncology organized a Consensus Conference on the role of rehabilitation of motor impairments in children/adolescents affected by leukemia, central nervous system tumors, and bone cancer to state recommendations to improve clinical practice. This paper includes the consensus on the rehabilitation of children and adolescents with these cancers.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141564023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of a major varicella zoster exposure in a pediatric oncology population. 在儿科肿瘤患者中处理重大水痘带状疱疹暴露。

IF 1.2 4区医学

Pediatric Hematology and Oncology Pub Date : 2024-08-01 Epub Date: 2024-02-20 DOI: 10.1080/08880018.2024.2315456

Carol Rossetto, Kent Sepkowitz, Jill Ackerman, Rachel Corke, Nina J Pickett, Wini Cudjoe, Janet Eagan, Mini Kamboj, Richard J O'Reilly, Farid Boulad

{"title":"Management of a major varicella zoster exposure in a pediatric oncology population.","authors":"Carol Rossetto, Kent Sepkowitz, Jill Ackerman, Rachel Corke, Nina J Pickett, Wini Cudjoe, Janet Eagan, Mini Kamboj, Richard J O'Reilly, Farid Boulad","doi":"10.1080/08880018.2024.2315456","DOIUrl":"10.1080/08880018.2024.2315456","url":null,"abstract":"Management of the exposure of pediatric oncology patients to varicella zoster virus (VZV) is controversial. We report the exposure of 56 patients to a single child with chicken pox at a pediatric cancer housing facility and describe our strategic approach for their management. We reviewed the immune and clinical status of 56 children with cancer receiving ongoing treatment at Memorial Sloan Kettering Cancer Center (MSK) who, while living at a pediatric cancer housing facility, were exposed to the index patient. The management of patients exposed included: (1) determination of immune status, (2) availability of vaccination history or VZV disease prophylaxis, (3) exposure status and subsequent isolation during the period of incubation, and (4) VZV disease prophylaxis. In addition to the 56 patients exposed to the index case, eight children with cancer treated at other facilities and 11 healthy siblings living in the facility were exposed. Of the 56 MSK patients, 21 were classified as immunosuppressed and received varicella zoster immune globulin (human), intravenous standard immune globulin, or acyclovir based on serostatus and immune function. The cohort was followed for 4 weeks after the exposure and no secondary infections were diagnosed. We performed a risk assessment and created a management plan to control and prevent further exposure and development of disease. No secondary cases developed. This strategic approach could serve as a model for the management of VZV exposure for other pediatric oncology centers.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139913178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Co-transplantation of umbilical cord mesenchymal stem cells and peripheral blood stem cells in children and adolescents with refractory or relapsed severe aplastic anemia. 为难治性或复发性重型再生障碍性贫血的儿童和青少年联合移植脐带间充质干细胞和外周血干细胞。

IF 1.2 4区医学

Pediatric Hematology and Oncology Pub Date : 2024-08-01 Epub Date: 2024-03-04 DOI: 10.1080/08880018.2024.2324394

Fangfang Yuan, Minghui Li, Xudong Wei, Yuewen Fu

{"title":"Co-transplantation of umbilical cord mesenchymal stem cells and peripheral blood stem cells in children and adolescents with refractory or relapsed severe aplastic anemia.","authors":"Fangfang Yuan, Minghui Li, Xudong Wei, Yuewen Fu","doi":"10.1080/08880018.2024.2324394","DOIUrl":"10.1080/08880018.2024.2324394","url":null,"abstract":"To evaluate the co-transplantation efficacy of umbilical cord mesenchymal stem cells (UC-MSCs) and peripheral blood stem cells (PBSCs) as a novel approach for refractory or relapsed severe aplastic anemia (R/R SAA) in children and adolescents, thirty-two children and adolescents diagnosed with R/R SAA underwent a retrospective chart review. The patients were categorized into two groups based on the source of PBSCs: the matched sibling donor (MSD) group and the unrelated donor (UD) group. No adverse events related to UC-MSC infusion occurred in any of the patients. The median time for neutrophil engraftment was 13 days (range: 10-23 days), and for platelets, it was 15 days (range: 11-28 days). Acute GVHD of Grade I-II and moderate chronic GVHD were observed in 21.8 and 12.5% of cases, respectively. No statistically significant differences were found between the MSD and UD groups in terms of engraftment, GVHD, and complications, including infection and hemorrhagic cystitis. The median follow-up time was 38.6 months (range: 1.4-140.8 months). As of October 31, 2021, five patients had succumbed, while 27 (84.4%) survived. The 5-year OS rate showed no statistically significant difference between the MSD and UD groups (84.8 ± 10.0 vs. 82.4 ± 9.2%, p = 0.674). In conclusion, the application of UC-MSCs in the treatment of R/R SAA in PBSC transplantation is reliable and safe, they had no graft rejection, low incidence of severe GVHD which may have been contributed by the co-infusion of MSC.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140022292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0